NO811680L - Fremgangsmaate for fremstilling av pyridoksin-derivater - Google Patents
Fremgangsmaate for fremstilling av pyridoksin-derivaterInfo
- Publication number
- NO811680L NO811680L NO811680A NO811680A NO811680L NO 811680 L NO811680 L NO 811680L NO 811680 A NO811680 A NO 811680A NO 811680 A NO811680 A NO 811680A NO 811680 L NO811680 L NO 811680L
- Authority
- NO
- Norway
- Prior art keywords
- methyl
- formula
- pyridine
- radical
- acid
- Prior art date
Links
- 238000002360 preparation method Methods 0.000 title claims description 14
- 238000000034 method Methods 0.000 title claims description 12
- LXNHXLLTXMVWPM-UHFFFAOYSA-N pyridoxine Chemical class CC1=NC=C(CO)C(CO)=C1O LXNHXLLTXMVWPM-UHFFFAOYSA-N 0.000 title description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 claims description 63
- -1 alkyl radical Chemical class 0.000 claims description 33
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 claims description 24
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 claims description 21
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 claims description 18
- 150000003839 salts Chemical class 0.000 claims description 14
- 239000002253 acid Substances 0.000 claims description 13
- 239000012458 free base Substances 0.000 claims description 13
- 150000003227 pyridoxines Chemical class 0.000 claims description 13
- 239000001257 hydrogen Substances 0.000 claims description 12
- 229910052739 hydrogen Inorganic materials 0.000 claims description 12
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 claims description 11
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 claims description 11
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 9
- YIPPKIQUGPYVFP-UHFFFAOYSA-N 1-[4,5-bis(hydroxymethyl)-2-methylpyridin-3-yl]oxy-3-[2-(2-methylphenoxy)ethylamino]propan-2-ol Chemical compound CC1=CC=CC=C1OCCNCC(O)COC1=C(C)N=CC(CO)=C1CO YIPPKIQUGPYVFP-UHFFFAOYSA-N 0.000 claims description 7
- 150000003254 radicals Chemical class 0.000 claims description 7
- 239000002904 solvent Substances 0.000 claims description 7
- 235000006408 oxalic acid Nutrition 0.000 claims description 6
- OFOBLEOULBTSOW-UHFFFAOYSA-N Propanedioic acid Natural products OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 claims description 5
- 125000004432 carbon atom Chemical group C* 0.000 claims description 5
- 239000001530 fumaric acid Substances 0.000 claims description 5
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 claims description 5
- 239000011976 maleic acid Substances 0.000 claims description 5
- 238000004519 manufacturing process Methods 0.000 claims description 5
- 150000002924 oxiranes Chemical class 0.000 claims description 5
- WLJNZVDCPSBLRP-UHFFFAOYSA-N pamoic acid Chemical compound C1=CC=C2C(CC=3C4=CC=CC=C4C=C(C=3O)C(=O)O)=C(O)C(C(O)=O)=CC2=C1 WLJNZVDCPSBLRP-UHFFFAOYSA-N 0.000 claims description 5
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 5
- 125000001424 substituent group Chemical group 0.000 claims description 5
- LLFSRHZTWRJCBS-UHFFFAOYSA-N 1-[4,5-bis(hydroxymethyl)-2-methylpyridin-3-yl]oxy-3-[2-(2-methoxyphenoxy)ethylamino]propan-2-ol Chemical compound COC1=CC=CC=C1OCCNCC(O)COC1=C(C)N=CC(CO)=C1CO LLFSRHZTWRJCBS-UHFFFAOYSA-N 0.000 claims description 4
- 238000006243 chemical reaction Methods 0.000 claims description 4
- GKIPXFAANLTWBM-UHFFFAOYSA-N epibromohydrin Chemical compound BrCC1CO1 GKIPXFAANLTWBM-UHFFFAOYSA-N 0.000 claims description 4
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 4
- 238000010992 reflux Methods 0.000 claims description 4
- 150000008044 alkali metal hydroxides Chemical class 0.000 claims description 3
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 claims description 3
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical group [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 claims description 2
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical group [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 claims description 2
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Chemical group BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 claims description 2
- 229910052794 bromium Chemical group 0.000 claims description 2
- 239000000460 chlorine Chemical group 0.000 claims description 2
- 229910052801 chlorine Inorganic materials 0.000 claims description 2
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims description 2
- 239000011737 fluorine Substances 0.000 claims description 2
- 229910052731 fluorine Inorganic materials 0.000 claims description 2
- 125000001153 fluoro group Chemical group F* 0.000 claims description 2
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 claims description 2
- 150000007522 mineralic acids Chemical class 0.000 claims description 2
- 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 claims description 2
- 150000007524 organic acids Chemical class 0.000 claims description 2
- 125000003854 p-chlorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1Cl 0.000 claims description 2
- 125000002924 primary amino group Chemical class [H]N([H])* 0.000 claims 4
- 150000002431 hydrogen Chemical class 0.000 claims 2
- 230000002378 acidificating effect Effects 0.000 claims 1
- 150000001875 compounds Chemical class 0.000 description 58
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 36
- 239000000203 mixture Substances 0.000 description 26
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 24
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 18
- 230000000694 effects Effects 0.000 description 15
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 14
- 239000000243 solution Substances 0.000 description 12
- 238000012360 testing method Methods 0.000 description 11
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 10
- 238000002844 melting Methods 0.000 description 10
- 230000008018 melting Effects 0.000 description 10
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 9
- 241000282472 Canis lupus familiaris Species 0.000 description 8
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 8
- PCLIMKBDDGJMGD-UHFFFAOYSA-N N-bromosuccinimide Chemical compound BrN1C(=O)CCC1=O PCLIMKBDDGJMGD-UHFFFAOYSA-N 0.000 description 8
- ZAFNJMIOTHYJRJ-UHFFFAOYSA-N Diisopropyl ether Chemical compound CC(C)OC(C)C ZAFNJMIOTHYJRJ-UHFFFAOYSA-N 0.000 description 7
- 230000004872 arterial blood pressure Effects 0.000 description 7
- UCTWMZQNUQWSLP-VIFPVBQESA-N (R)-adrenaline Chemical compound CNC[C@H](O)C1=CC=C(O)C(O)=C1 UCTWMZQNUQWSLP-VIFPVBQESA-N 0.000 description 6
- 229930182837 (R)-adrenaline Natural products 0.000 description 6
- 241001465754 Metazoa Species 0.000 description 6
- 230000001466 anti-adreneric effect Effects 0.000 description 6
- 229960005139 epinephrine Drugs 0.000 description 6
- 230000000144 pharmacologic effect Effects 0.000 description 6
- 238000002474 experimental method Methods 0.000 description 5
- 210000004165 myocardium Anatomy 0.000 description 5
- 150000003222 pyridines Chemical class 0.000 description 5
- 229940126062 Compound A Drugs 0.000 description 4
- NLDMNSXOCDLTTB-UHFFFAOYSA-N Heterophylliin A Natural products O1C2COC(=O)C3=CC(O)=C(O)C(O)=C3C3=C(O)C(O)=C(O)C=C3C(=O)OC2C(OC(=O)C=2C=C(O)C(O)=C(O)C=2)C(O)C1OC(=O)C1=CC(O)=C(O)C(O)=C1 NLDMNSXOCDLTTB-UHFFFAOYSA-N 0.000 description 4
- 206010020772 Hypertension Diseases 0.000 description 4
- 241000700159 Rattus Species 0.000 description 4
- 230000003276 anti-hypertensive effect Effects 0.000 description 4
- WEXRUCMBJFQVBZ-UHFFFAOYSA-N pentobarbital Chemical compound CCCC(C)C1(CC)C(=O)NC(=O)NC1=O WEXRUCMBJFQVBZ-UHFFFAOYSA-N 0.000 description 4
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 4
- 238000003756 stirring Methods 0.000 description 4
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical class CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 3
- 206010002383 Angina Pectoris Diseases 0.000 description 3
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 3
- WVDDGKGOMKODPV-UHFFFAOYSA-N Benzyl alcohol Chemical compound OCC1=CC=CC=C1 WVDDGKGOMKODPV-UHFFFAOYSA-N 0.000 description 3
- 208000001953 Hypotension Diseases 0.000 description 3
- BSKHPKMHTQYZBB-UHFFFAOYSA-N alpha-methylpyridine Natural products CC1=CC=CC=N1 BSKHPKMHTQYZBB-UHFFFAOYSA-N 0.000 description 3
- 239000007864 aqueous solution Substances 0.000 description 3
- 150000003943 catecholamines Chemical class 0.000 description 3
- 238000001816 cooling Methods 0.000 description 3
- 239000003937 drug carrier Substances 0.000 description 3
- 238000001914 filtration Methods 0.000 description 3
- 230000036543 hypotension Effects 0.000 description 3
- 230000001077 hypotensive effect Effects 0.000 description 3
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 3
- 239000012074 organic phase Substances 0.000 description 3
- 239000000546 pharmaceutical excipient Substances 0.000 description 3
- 150000003141 primary amines Chemical class 0.000 description 3
- 239000000047 product Substances 0.000 description 3
- DXYUDCFZHJXQQR-UHFFFAOYSA-N 2-(2-methylphenoxy)ethanamine Chemical compound CC1=CC=CC=C1OCCN DXYUDCFZHJXQQR-UHFFFAOYSA-N 0.000 description 2
- OSDWBNJEKMUWAV-UHFFFAOYSA-N Allyl chloride Chemical compound ClCC=C OSDWBNJEKMUWAV-UHFFFAOYSA-N 0.000 description 2
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 2
- KTDIRJXULRVRMD-UHFFFAOYSA-N C(C(=O)O)(=O)O.OCC1=C(C(=NC=C1CO)C)OCC(CNCCOC1=C(C=CC=C1)C)O.C(C(=O)O)(=O)O.C(C(=O)O)(=O)O.OCC1=C(C(=NC=C1CO)C)OCC(CNCCOC1=C(C=CC=C1)C)O Chemical compound C(C(=O)O)(=O)O.OCC1=C(C(=NC=C1CO)C)OCC(CNCCOC1=C(C=CC=C1)C)O.C(C(=O)O)(=O)O.C(C(=O)O)(=O)O.OCC1=C(C(=NC=C1CO)C)OCC(CNCCOC1=C(C=CC=C1)C)O KTDIRJXULRVRMD-UHFFFAOYSA-N 0.000 description 2
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 2
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Chemical compound OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 2
- 241000699670 Mus sp. Species 0.000 description 2
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 description 2
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 2
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 2
- 230000003444 anaesthetic effect Effects 0.000 description 2
- 230000003288 anthiarrhythmic effect Effects 0.000 description 2
- 239000003416 antiarrhythmic agent Substances 0.000 description 2
- 208000037849 arterial hypertension Diseases 0.000 description 2
- 230000036772 blood pressure Effects 0.000 description 2
- 210000004556 brain Anatomy 0.000 description 2
- 239000003874 central nervous system depressant Substances 0.000 description 2
- 230000002490 cerebral effect Effects 0.000 description 2
- 238000002425 crystallisation Methods 0.000 description 2
- 230000008025 crystallization Effects 0.000 description 2
- 238000000354 decomposition reaction Methods 0.000 description 2
- 230000003001 depressive effect Effects 0.000 description 2
- 238000001035 drying Methods 0.000 description 2
- DQYBDCGIPTYXML-UHFFFAOYSA-N ethoxyethane;hydrate Chemical compound O.CCOCC DQYBDCGIPTYXML-UHFFFAOYSA-N 0.000 description 2
- 238000010253 intravenous injection Methods 0.000 description 2
- 239000003589 local anesthetic agent Substances 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- 229910052757 nitrogen Inorganic materials 0.000 description 2
- 125000004433 nitrogen atom Chemical group N* 0.000 description 2
- 229960001412 pentobarbital Drugs 0.000 description 2
- 229910000027 potassium carbonate Inorganic materials 0.000 description 2
- 238000001953 recrystallisation Methods 0.000 description 2
- BJOIZNZVOZKDIG-MDEJGZGSSA-N reserpine Chemical compound O([C@H]1[C@@H]([C@H]([C@H]2C[C@@H]3C4=C([C]5C=CC(OC)=CC5=N4)CCN3C[C@H]2C1)C(=O)OC)OC)C(=O)C1=CC(OC)=C(OC)C(OC)=C1 BJOIZNZVOZKDIG-MDEJGZGSSA-N 0.000 description 2
- 229910052708 sodium Inorganic materials 0.000 description 2
- 239000011734 sodium Substances 0.000 description 2
- 229910052938 sodium sulfate Inorganic materials 0.000 description 2
- 235000011152 sodium sulphate Nutrition 0.000 description 2
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 238000004809 thin layer chromatography Methods 0.000 description 2
- DNXIKVLOVZVMQF-UHFFFAOYSA-N (3beta,16beta,17alpha,18beta,20alpha)-17-hydroxy-11-methoxy-18-[(3,4,5-trimethoxybenzoyl)oxy]-yohimban-16-carboxylic acid, methyl ester Natural products C1C2CN3CCC(C4=CC=C(OC)C=C4N4)=C4C3CC2C(C(=O)OC)C(O)C1OC(=O)C1=CC(OC)=C(OC)C(OC)=C1 DNXIKVLOVZVMQF-UHFFFAOYSA-N 0.000 description 1
- DRTQHJPVMGBUCF-UCVXFZOQSA-N 1-[(2s,3s,4s,5s)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]pyrimidine-2,4-dione Chemical compound O[C@H]1[C@H](O)[C@H](CO)O[C@@H]1N1C(=O)NC(=O)C=C1 DRTQHJPVMGBUCF-UCVXFZOQSA-N 0.000 description 1
- KLHPEWQLXDCKLY-UHFFFAOYSA-N 1-[4,5-bis(hydroxymethyl)-2-methylpyridin-3-yl]oxy-3-(1-phenylpropan-2-ylamino)propan-2-ol Chemical compound CC=1N=CC(CO)=C(CO)C=1OCC(O)CNC(C)CC1=CC=CC=C1 KLHPEWQLXDCKLY-UHFFFAOYSA-N 0.000 description 1
- LVIWITRYEMGJGO-UHFFFAOYSA-N 1-[4,5-bis(hydroxymethyl)-2-methylpyridin-3-yl]oxy-3-(2-phenoxyethylamino)propan-2-ol Chemical compound CC1=NC=C(CO)C(CO)=C1OCC(O)CNCCOC1=CC=CC=C1 LVIWITRYEMGJGO-UHFFFAOYSA-N 0.000 description 1
- KHHMWNGGWGPFSK-UHFFFAOYSA-N 1-[4,5-bis(hydroxymethyl)-2-methylpyridin-3-yl]oxy-3-(2-phenoxypropylamino)propan-2-ol Chemical compound C=1C=CC=CC=1OC(C)CNCC(O)COC1=C(C)N=CC(CO)=C1CO KHHMWNGGWGPFSK-UHFFFAOYSA-N 0.000 description 1
- WLDHQZKZLUMDEV-UHFFFAOYSA-N 1-[4,5-bis(hydroxymethyl)-2-methylpyridin-3-yl]oxy-3-[2-(2-ethylphenoxy)ethylamino]propan-2-ol Chemical compound CCC1=CC=CC=C1OCCNCC(O)COC1=C(C)N=CC(CO)=C1CO WLDHQZKZLUMDEV-UHFFFAOYSA-N 0.000 description 1
- METALPSDOQHKOO-UHFFFAOYSA-N 1-[4,5-bis(hydroxymethyl)-2-methylpyridin-3-yl]oxy-3-[2-(2-methylphenoxy)ethylamino]propan-2-ol;dihydrochloride Chemical compound Cl.Cl.CC1=CC=CC=C1OCCNCC(O)COC1=C(C)N=CC(CO)=C1CO METALPSDOQHKOO-UHFFFAOYSA-N 0.000 description 1
- SLJLTFKYTSWRPH-UHFFFAOYSA-N 1-[4,5-bis(hydroxymethyl)-2-methylpyridin-3-yl]oxy-3-[2-(2-propan-2-ylphenoxy)ethylamino]propan-2-ol Chemical compound CC(C)C1=CC=CC=C1OCCNCC(O)COC1=C(C)N=CC(CO)=C1CO SLJLTFKYTSWRPH-UHFFFAOYSA-N 0.000 description 1
- HGEHVVOWIJAGOD-UHFFFAOYSA-N 1-[4,5-bis(hydroxymethyl)-2-methylpyridin-3-yl]oxy-3-[2-(2-propylphenoxy)ethylamino]propan-2-ol Chemical compound CCCC1=CC=CC=C1OCCNCC(O)COC1=C(C)N=CC(CO)=C1CO HGEHVVOWIJAGOD-UHFFFAOYSA-N 0.000 description 1
- LQNWAWMXSAJJMD-UHFFFAOYSA-N 1-[4,5-bis(hydroxymethyl)-2-methylpyridin-3-yl]oxy-3-[2-(3,5-dimethylphenoxy)ethylamino]propan-2-ol Chemical compound CC1=CC(C)=CC(OCCNCC(O)COC=2C(=C(CO)C=NC=2C)CO)=C1 LQNWAWMXSAJJMD-UHFFFAOYSA-N 0.000 description 1
- BZFOZYIBIVHMNV-UHFFFAOYSA-N 1-[4,5-bis(hydroxymethyl)-2-methylpyridin-3-yl]oxy-3-[2-(3-methylphenoxy)ethylamino]propan-2-ol Chemical compound CC1=CC=CC(OCCNCC(O)COC=2C(=C(CO)C=NC=2C)CO)=C1 BZFOZYIBIVHMNV-UHFFFAOYSA-N 0.000 description 1
- DAWDPZWIOCZEOP-UHFFFAOYSA-N 1-[4,5-bis(hydroxymethyl)-2-methylpyridin-3-yl]oxy-3-[2-(4-chlorophenoxy)ethylamino]propan-2-ol Chemical compound CC1=NC=C(CO)C(CO)=C1OCC(O)CNCCOC1=CC=C(Cl)C=C1 DAWDPZWIOCZEOP-UHFFFAOYSA-N 0.000 description 1
- XELRAMDRXLZAOW-UHFFFAOYSA-N 1-[4,5-bis(hydroxymethyl)-2-methylpyridin-3-yl]oxy-3-[2-(4-methylphenoxy)ethylamino]propan-2-ol Chemical compound C1=CC(C)=CC=C1OCCNCC(O)COC1=C(C)N=CC(CO)=C1CO XELRAMDRXLZAOW-UHFFFAOYSA-N 0.000 description 1
- SKJJQWISZSHHOI-UHFFFAOYSA-N 1-[4,5-bis(hydroxymethyl)-2-methylpyridin-3-yl]oxy-3-[2-(5-methyl-2-propan-2-ylphenoxy)ethylamino]propan-2-ol Chemical compound CC(C)C1=CC=C(C)C=C1OCCNCC(O)COC1=C(C)N=CC(CO)=C1CO SKJJQWISZSHHOI-UHFFFAOYSA-N 0.000 description 1
- WBVWFLPIYURCJY-UHFFFAOYSA-N 1-[4,5-bis(hydroxymethyl)-2-methylpyridin-3-yl]oxy-3-[3-(3,4-dimethylphenoxy)propylamino]propan-2-ol Chemical compound C1=C(C)C(C)=CC=C1OCCCNCC(O)COC1=C(C)N=CC(CO)=C1CO WBVWFLPIYURCJY-UHFFFAOYSA-N 0.000 description 1
- 108060003345 Adrenergic Receptor Proteins 0.000 description 1
- 102000017910 Adrenergic receptor Human genes 0.000 description 1
- 208000014644 Brain disease Diseases 0.000 description 1
- IEHQPYIKUXOPIC-WLHGVMLRSA-N C(\C=C\C(=O)O)(=O)O.OCC1=C(C(=NC=C1CO)C)OCC(CNCCOC1=C(C=CC=C1)C)O Chemical compound C(\C=C\C(=O)O)(=O)O.OCC1=C(C(=NC=C1CO)C)OCC(CNCCOC1=C(C=CC=C1)C)O IEHQPYIKUXOPIC-WLHGVMLRSA-N 0.000 description 1
- HNUALPPJLMYHDK-UHFFFAOYSA-N C[CH]C Chemical compound C[CH]C HNUALPPJLMYHDK-UHFFFAOYSA-N 0.000 description 1
- 206010008097 Cerebral circulatory failure Diseases 0.000 description 1
- RRHGJUQNOFWUDK-UHFFFAOYSA-N Isoprene Chemical compound CC(=C)C=C RRHGJUQNOFWUDK-UHFFFAOYSA-N 0.000 description 1
- 241000209082 Lolium Species 0.000 description 1
- 208000019695 Migraine disease Diseases 0.000 description 1
- YSEXMKHXIOCEJA-FVFQAYNVSA-N Nicergoline Chemical compound C([C@@H]1C[C@]2([C@H](N(C)C1)CC=1C3=C2C=CC=C3N(C)C=1)OC)OC(=O)C1=CN=CC(Br)=C1 YSEXMKHXIOCEJA-FVFQAYNVSA-N 0.000 description 1
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical group C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 1
- LCQMZZCPPSWADO-UHFFFAOYSA-N Reserpilin Natural products COC(=O)C1COCC2CN3CCc4c([nH]c5cc(OC)c(OC)cc45)C3CC12 LCQMZZCPPSWADO-UHFFFAOYSA-N 0.000 description 1
- QEVHRUUCFGRFIF-SFWBKIHZSA-N Reserpine Natural products O=C(OC)[C@@H]1[C@H](OC)[C@H](OC(=O)c2cc(OC)c(OC)c(OC)c2)C[C@H]2[C@@H]1C[C@H]1N(C2)CCc2c3c([nH]c12)cc(OC)cc3 QEVHRUUCFGRFIF-SFWBKIHZSA-N 0.000 description 1
- UIIMBOGNXHQVGW-DEQYMQKBSA-M Sodium bicarbonate-14C Chemical compound [Na+].O[14C]([O-])=O UIIMBOGNXHQVGW-DEQYMQKBSA-M 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 208000001871 Tachycardia Diseases 0.000 description 1
- CSDBYZOMQILAAI-UHFFFAOYSA-N [5-(3-bromo-2-hydroxypropoxy)-6-methyl-4-(methylcarbamoyloxymethyl)pyridin-3-yl]methyl n-methylcarbamate Chemical compound CNC(=O)OCC1=CN=C(C)C(OCC(O)CBr)=C1COC(=O)NC CSDBYZOMQILAAI-UHFFFAOYSA-N 0.000 description 1
- 230000001133 acceleration Effects 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 231100000215 acute (single dose) toxicity testing Toxicity 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 231100000403 acute toxicity Toxicity 0.000 description 1
- 230000007059 acute toxicity Effects 0.000 description 1
- 238000011047 acute toxicity test Methods 0.000 description 1
- 230000001800 adrenalinergic effect Effects 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 239000000783 alginic acid Substances 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 229960001126 alginic acid Drugs 0.000 description 1
- 150000004781 alginic acids Chemical class 0.000 description 1
- 229910021529 ammonia Inorganic materials 0.000 description 1
- 230000003257 anti-anginal effect Effects 0.000 description 1
- 125000004429 atom Chemical group 0.000 description 1
- 239000002585 base Substances 0.000 description 1
- 235000019445 benzyl alcohol Nutrition 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 239000007795 chemical reaction product Substances 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 230000002526 effect on cardiovascular system Effects 0.000 description 1
- 239000003480 eluent Substances 0.000 description 1
- 238000005265 energy consumption Methods 0.000 description 1
- 239000012259 ether extract Substances 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 210000001105 femoral artery Anatomy 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 239000007903 gelatin capsule Substances 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 125000004435 hydrogen atom Chemical group [H]* 0.000 description 1
- 125000004029 hydroxymethyl group Chemical group [H]OC([H])([H])* 0.000 description 1
- 239000002198 insoluble material Substances 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 239000012948 isocyanate Substances 0.000 description 1
- 150000002513 isocyanates Chemical class 0.000 description 1
- 230000005923 long-lasting effect Effects 0.000 description 1
- 231100000053 low toxicity Toxicity 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- HAMGRBXTJNITHG-UHFFFAOYSA-N methyl isocyanate Chemical compound CN=C=O HAMGRBXTJNITHG-UHFFFAOYSA-N 0.000 description 1
- 206010027599 migraine Diseases 0.000 description 1
- 238000006386 neutralization reaction Methods 0.000 description 1
- 229960003642 nicergoline Drugs 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 230000036581 peripheral resistance Effects 0.000 description 1
- 239000012071 phase Substances 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 125000002572 propoxy group Chemical group [*]OC([H])([H])C(C([H])([H])[H])([H])[H] 0.000 description 1
- 235000008160 pyridoxine Nutrition 0.000 description 1
- 239000011677 pyridoxine Substances 0.000 description 1
- 239000012429 reaction media Substances 0.000 description 1
- 102000005962 receptors Human genes 0.000 description 1
- 108020003175 receptors Proteins 0.000 description 1
- 229960003147 reserpine Drugs 0.000 description 1
- MDMGHDFNKNZPAU-UHFFFAOYSA-N roserpine Natural products C1C2CN3CCC(C4=CC=C(OC)C=C4N4)=C4C3CC2C(OC(C)=O)C(OC)C1OC(=O)C1=CC(OC)=C(OC)C(OC)=C1 MDMGHDFNKNZPAU-UHFFFAOYSA-N 0.000 description 1
- RMAQACBXLXPBSY-UHFFFAOYSA-N silicic acid Chemical compound O[Si](O)(O)O RMAQACBXLXPBSY-UHFFFAOYSA-N 0.000 description 1
- 235000012239 silicon dioxide Nutrition 0.000 description 1
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 1
- 235000017557 sodium bicarbonate Nutrition 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 230000006794 tachycardia Effects 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 235000012222 talc Nutrition 0.000 description 1
- LMBFAGIMSUYTBN-MPZNNTNKSA-N teixobactin Chemical compound C([C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H](CCC(N)=O)C(=O)N[C@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H]1C(N[C@@H](C)C(=O)N[C@@H](C[C@@H]2NC(=N)NC2)C(=O)N[C@H](C(=O)O[C@H]1C)[C@@H](C)CC)=O)NC)C1=CC=CC=C1 LMBFAGIMSUYTBN-MPZNNTNKSA-N 0.000 description 1
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 1
- 230000002792 vascular Effects 0.000 description 1
- 230000002861 ventricular Effects 0.000 description 1
- 229940011671 vitamin b6 Drugs 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/62—Oxygen or sulfur atoms
- C07D213/63—One oxygen atom
- C07D213/65—One oxygen atom attached in position 3 or 5
- C07D213/66—One oxygen atom attached in position 3 or 5 having in position 3 an oxygen atom and in each of the positions 4 and 5 a carbon atom bound to an oxygen, sulphur, or nitrogen atom, e.g. pyridoxal
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/08—Vasodilators for multiple indications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/04—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Pyridine Compounds (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB8016516 | 1980-05-19 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| NO811680L true NO811680L (no) | 1981-11-20 |
Family
ID=10513518
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NO811680A NO811680L (no) | 1980-05-19 | 1981-05-18 | Fremgangsmaate for fremstilling av pyridoksin-derivater |
Country Status (32)
| Country | Link |
|---|---|
| US (1) | US4374841A (es) |
| EP (1) | EP0040591B1 (es) |
| JP (1) | JPS5711966A (es) |
| AR (1) | AR226356A1 (es) |
| AT (1) | ATE3859T1 (es) |
| AU (1) | AU542463B2 (es) |
| BG (1) | BG35327A3 (es) |
| CA (1) | CA1152080A (es) |
| CS (1) | CS223842B2 (es) |
| DD (1) | DD159071A5 (es) |
| DE (1) | DE3160480D1 (es) |
| DK (1) | DK217481A (es) |
| EG (1) | EG15890A (es) |
| ES (1) | ES502276A0 (es) |
| FI (1) | FI811525L (es) |
| GR (1) | GR82343B (es) |
| HU (1) | HU183441B (es) |
| IE (1) | IE51179B1 (es) |
| IL (1) | IL62602A (es) |
| IN (1) | IN151915B (es) |
| IS (1) | IS1183B6 (es) |
| MA (1) | MA19147A1 (es) |
| NO (1) | NO811680L (es) |
| NZ (1) | NZ196766A (es) |
| OA (1) | OA06811A (es) |
| PL (1) | PL129213B1 (es) |
| PT (1) | PT72992B (es) |
| RO (1) | RO81943A (es) |
| SU (1) | SU1077566A3 (es) |
| YU (1) | YU126281A (es) |
| ZA (1) | ZA812448B (es) |
| ZW (1) | ZW9681A1 (es) |
Families Citing this family (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4663354A (en) * | 1984-04-26 | 1987-05-05 | Klinge Pharma Gmbh | Use of etilefrin and etilefrin pivalate in the long term treatment of circulatory disorders not due to hypotonia |
| DE3519693A1 (de) * | 1985-06-01 | 1987-01-02 | Basf Ag | Pyridin-derivate, ihre herstellung und verwendung |
| US6051587A (en) * | 1998-04-16 | 2000-04-18 | Medicure, Inc. | Treatment of iatrogenic and age-related hypertension and pharmaceutical compositions useful therein |
| US6043259A (en) * | 1998-07-09 | 2000-03-28 | Medicure Inc. | Treatment of cardiovascular and related pathologies |
| ATE306489T1 (de) | 1999-03-08 | 2005-10-15 | Medicure Inc | Pyridoxal-analoge zur behandlung von störungen ausgelöst durch einen vitamin b6 mangel |
| AU5840200A (en) | 1999-07-13 | 2001-01-30 | Medicure Inc. | Treatment of diabetes and related pathologies |
| WO2001013900A2 (en) | 1999-08-24 | 2001-03-01 | Medicure International Inc. | Compositions for the treatment of cardiovascular diseases containing pyridoxal compounds and cardiovascular compounds |
| US7442689B2 (en) * | 2000-02-29 | 2008-10-28 | Medicure International Inc. | Cardioprotective phosphonates and malonates |
| DE60110054T2 (de) | 2000-02-29 | 2006-03-09 | Medicure International Inc. | Cardioprotektive phosphonate |
| US6586414B2 (en) | 2000-03-28 | 2003-07-01 | Medicure International Inc. | Treatment of cerebrovascular disease |
| US6548519B1 (en) | 2001-07-06 | 2003-04-15 | Medicure International Inc. | Pyridoxine and pyridoxal analogues: novel uses |
| US6897228B2 (en) * | 2000-07-07 | 2005-05-24 | Medicure International Inc. | Pyridoxine and pyridoxal analogues: new uses |
| NZ523815A (en) | 2000-07-07 | 2004-07-30 | Medicure Int Inc | Pyridoxine and pyridoxal analogues: cardiovascular therapeutics |
| US20040121988A1 (en) * | 2001-03-28 | 2004-06-24 | Medicure International Inc. | Treatment of cerebrovascular disease |
| JP4048166B2 (ja) * | 2002-11-18 | 2008-02-13 | 三井製糖株式会社 | 血糖値上昇抑制剤及び体脂肪蓄積抑制剤並びに食用材料 |
| US20040186077A1 (en) * | 2003-03-17 | 2004-09-23 | Medicure International Inc. | Novel heteroaryl phosphonates as cardioprotective agents |
| AU2004224566A1 (en) * | 2003-03-27 | 2004-10-07 | Medicure Inc. | Compositions for treating angina |
| US20060019929A1 (en) * | 2004-07-07 | 2006-01-26 | Albert Friesen | Combination therapies employing platelet aggregation drugs |
| US20070060549A1 (en) * | 2004-08-10 | 2007-03-15 | Friesen Albert D | Combination therapies employing ace inhibitors and uses thereof for the treatment of diabetic disorders |
| WO2006050598A1 (en) * | 2004-10-28 | 2006-05-18 | Medicure International Inc. | Dual antiplatelet/anticoagulant pyridoxine analogs |
| US20060094749A1 (en) * | 2004-10-28 | 2006-05-04 | Medicure International Inc. | Substituted pyridoxines as anti-platelet agents |
| US7459468B2 (en) * | 2004-10-28 | 2008-12-02 | Medicure International, Inc. | Aryl sulfonic pyridoxines as antiplatelet agents |
| JP2009517411A (ja) * | 2005-11-28 | 2009-04-30 | メディキュア インターナショナル インコーポレーテッド | 心血管及び関連病状の処置のための調剤 |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4115575A (en) * | 1973-02-20 | 1978-09-19 | Ciba-Geigy Corporation | 2-(3-Amino-2-hydroxy-propoxy)-pyrazines |
| AR206801A1 (es) * | 1973-02-20 | 1976-08-23 | Ciba Geigy Ag | Procedimiento para la elaboracion de derivados del 1-pirid loxi-2-hidroxi-3-amino-propano |
| GB1485919A (en) * | 1975-08-12 | 1977-09-14 | Grindstedvaerket As | Pyridine derivatives |
| DE2711655A1 (de) * | 1977-03-17 | 1978-09-21 | Basf Ag | Pyridinyl-aminoalkylaether |
| US4210653A (en) * | 1978-06-27 | 1980-07-01 | Merck & Co., Inc. | Pyridyloxypropanolamines |
-
1981
- 1981-04-07 IL IL62602A patent/IL62602A/xx unknown
- 1981-04-08 NZ NZ196766A patent/NZ196766A/en unknown
- 1981-04-10 IS IS2631A patent/IS1183B6/is unknown
- 1981-04-13 ZA ZA00812448A patent/ZA812448B/xx unknown
- 1981-04-14 GR GR64686A patent/GR82343B/el unknown
- 1981-04-27 ZW ZW96/81A patent/ZW9681A1/xx unknown
- 1981-04-28 BG BG051875A patent/BG35327A3/xx unknown
- 1981-05-02 IN IN465/CAL/81A patent/IN151915B/en unknown
- 1981-05-07 AR AR285225A patent/AR226356A1/es active
- 1981-05-07 PT PT72992A patent/PT72992B/pt unknown
- 1981-05-11 US US06/262,449 patent/US4374841A/en not_active Expired - Fee Related
- 1981-05-12 EG EG260/81A patent/EG15890A/xx active
- 1981-05-13 MA MA19356A patent/MA19147A1/fr unknown
- 1981-05-13 AU AU70535/81A patent/AU542463B2/en not_active Ceased
- 1981-05-15 CS CS813634A patent/CS223842B2/cs unknown
- 1981-05-15 CA CA000377739A patent/CA1152080A/en not_active Expired
- 1981-05-15 EP EP81870023A patent/EP0040591B1/fr not_active Expired
- 1981-05-15 PL PL1981231193A patent/PL129213B1/pl unknown
- 1981-05-15 AT AT81870023T patent/ATE3859T1/de not_active IP Right Cessation
- 1981-05-15 IE IE1085/81A patent/IE51179B1/en unknown
- 1981-05-15 JP JP7407681A patent/JPS5711966A/ja active Pending
- 1981-05-15 YU YU01262/81A patent/YU126281A/xx unknown
- 1981-05-15 DE DE8181870023T patent/DE3160480D1/de not_active Expired
- 1981-05-18 SU SU813289800A patent/SU1077566A3/ru active
- 1981-05-18 FI FI811525A patent/FI811525L/fi not_active Application Discontinuation
- 1981-05-18 NO NO811680A patent/NO811680L/no unknown
- 1981-05-18 RO RO81104319A patent/RO81943A/ro unknown
- 1981-05-18 DK DK217481A patent/DK217481A/da not_active Application Discontinuation
- 1981-05-18 DD DD81230039A patent/DD159071A5/de unknown
- 1981-05-18 OA OA57404A patent/OA06811A/xx unknown
- 1981-05-18 ES ES502276A patent/ES502276A0/es active Granted
- 1981-05-18 HU HU811402A patent/HU183441B/hu unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NO811680L (no) | Fremgangsmaate for fremstilling av pyridoksin-derivater | |
| US4337257A (en) | Gastric acid secretion inhibiting substituted 2-(2-benzimidazolyl)-pyridines, their preparation, pharmaceutical preparations containing same, and method for inhibiting gastric acid secretion | |
| CS196290B2 (en) | Process for preparing new compounds | |
| CS275837B6 (en) | Method of production of new cycloalkan0-|1,2b¨-indole sulfonamides | |
| EP0370901A1 (fr) | Nouveaux dérivés du chromanne actifs sur le système nerveux central, leur procédé de préparation et les compositions pharmaceutiques en contenant | |
| EP0054417A1 (en) | Indole thromboxane synthetase inhibitors, processes for their preparation, and pharmaceutical compositions containing them | |
| DE19512639A1 (de) | Benzonitrile und -fluoride | |
| EP0612730B1 (en) | O-aryl ethers of morphinans | |
| EP0109866B1 (fr) | Nouveaux dérivés de la sulfonylurée, leurs procédés de préparation et les compositions pharmaceutiques les renfermant | |
| CA2506735A1 (en) | Indole derivatives as somatostatin agonists or antagonists | |
| US5041444A (en) | Benzoxepin derivatives | |
| NO822122L (no) | Fremgangsmaate for fremstilling av amidobenzamider | |
| US4642310A (en) | Circulation-active tetrahydrothienopyridines | |
| US4395559A (en) | 2,3-Indoledione derivatives | |
| EP0250264A1 (en) | Irreversible dopamine-Beta-hydroxylase inhibitors | |
| JP2001511799A (ja) | オキシド−スクアレンシクラーゼ阻害剤として有用なヘテロ環式化合物 | |
| CZ4296A3 (en) | Novel (1-phenyl-1-heterocyclyl)methanol and (1-phenyl-1-heterocyclyl)methylamine derivatives | |
| EP0718290A1 (en) | Carboxyalkyl heterocyclic derivatives | |
| US4278798A (en) | 1-Ethyl-1,4-dihydro-6-(2-naphthyl)-4-oxonicotinic acid and esters thereof | |
| US5962454A (en) | Neovascularization inhibitor | |
| JPH03167184A (ja) | Ｎ―ベンジルトロパンアミド類 | |
| NO792275L (no) | Fremgangsmaate for fremstilling av farmakologisk aktive pyrazolo-pyridinderivater | |
| JPH02258749A (ja) | ポリヒドロキシベンジルオキシプロパノールアミン | |
| US4314063A (en) | 1-Ethyl-1,4,5,6-tetrahydro-6-(2-naphthyl)-4-oxo-nicotinic acid and lower alkyl esters thereof | |
| US4374261A (en) | 1-Ethyl-1,4-dihydro-6-(2-naphthyl)-4-oxo-nicotinic acid and esters thereof |